公开(公告)号：US08993598B2

公开(公告)日：2015-03-31

申请号：US14043018

申请日：2013-10-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Haruyuki Nishida ,  Yasuyoshi Arikawa ,  Ikuo Fujimori

IPC: A61K31/4439 ,  A61K31/444 ,  C07D401/14

CPC classification number: A61K31/444 ,  C07D401/14

Abstract: The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, R4 and R6 are each a hydrogen atom, a halogen atom or a C1-6 alkyl group optionally substituted by halogen, R5 is a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, and R7 is a hydrogen atom or a C1-6 alkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.

公开(公告)号：US11584737B2

公开(公告)日：2023-02-21

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji Ono ,  Masahiro Ito ,  Toshio Tanaka ,  Moriteru Asano ,  Takaharu Hirayama ,  Jun Fujimoto ,  Nobuki Sakauchi ,  Yasuhiro Hirata ,  Akinori Toita ,  Nao Morishita ,  Hironori Kokubo ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Douglas Robert Cary ,  Ryo Mizojiri ,  Nobuo Cho ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Yasuyoshi Arikawa

IPC: C07D401/14 ,  C07D403/14 ,  A61P35/00 ,  C07D213/84 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11230545B2

公开(公告)日：2022-01-25

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US10435399B2

公开(公告)日：2019-10-08

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Osamu Kubo ,  Fumiaki Kikuchi ,  Takeshi Yasui ,  Keiko Kakegawa ,  Zenichi Ikeda ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Akinori Toita ,  Takuto Kojima ,  Yasutomi Asano ,  Ayumu Sato ,  Hironobu Maezaki ,  Shinobu Sasaki ,  Hironori Kokubo ,  Misaki Homma ,  Minoru Sasaki ,  Yasuhiro Imaeda

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D487/04 ,  A61P25/28 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20150336964A1

公开(公告)日：2015-11-26

申请号：US14814878

申请日：2015-07-31

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasuyoshi Arikawa ,  Benjamin Jones ,  Betty Lam ,  Christopher Smith ,  Masashi Takahashi ,  Qing Dong ,  Victoria Feher ,  Zhe Nie

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/527 ,  A61K31/437 ,  C07D487/10 ,  A61K31/519 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即， 癌症）以及其它疾病，疾病和表示SYK抑制的病症。

公开(公告)号：US12084436B2

公开(公告)日：2024-09-10

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Hideyuki Sugiyama ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Osamu Kubo ,  Akinori Toita ,  Takuto Kojima ,  Fumiaki Kikuchi ,  Minoru Sasaki ,  Misaki Homma ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Shiinobu Sasaki ,  Ayumu Sato ,  Hirotaka Kamitani ,  Yasutomi Asano ,  Hironori Kokubo ,  Masato Yoshikawa

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US09108970B2

公开(公告)日：2015-08-18

申请号：US13886032

申请日：2013-05-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasuyoshi Arikawa ,  Benjamin Jones ,  Betty Lam ,  Christopher Smith ,  Masashi Takahashi ,  Qing Dong ,  Victoria Feher ,  Zhe Nie

IPC: C07D471/04 ,  A61K31/437 ,  A61P11/06 ,  A61P35/00 ,  A61P17/06 ,  A61P29/00 ,  A61P11/08 ,  A61P37/02 ,  A61K31/527 ,  A61K45/06 ,  C07D487/10 ,  C07D519/00 ,  C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即， 癌症）以及其它疾病，疾病和表示SYK抑制的病症。

公开(公告)号：US20140031393A1

公开(公告)日：2014-01-30

申请号：US14043018

申请日：2013-10-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Haruyuki Nishida ,  Yasuyoshi Arikawa ,  Ikuo Fujimori

IPC: A61K31/444

CPC classification number: A61K31/444 ,  C07D401/14

Abstract: The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, R4 and R6 are each a hydrogen atom, a halogen atom or a C1-6 alkyl group optionally substituted by halogen, R5 is a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, and R7 is a hydrogen atom or a C1-6 alkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.

Abstract translation: 本发明涉及由下式表示的化合物：其中A是具有至少一个取代基的吡啶基，其中R 1，R 2和R 3各自为氢原子，卤素原子，任选被卤素取代的C 1-6烷基或 任选被卤素取代的C 1-6烷氧基，R 4和R 6各自为氢原子，卤素原子或任选被卤素取代的C 1-6烷基，R 5为氢原子，卤素原子，C 1-6烷基 任选被卤素取代或被卤素任意取代的C 1-6烷氧基，R 7是氢原子或任选被卤素或其盐取代的C 1-6烷基，或含有它们的药物组合物。

公开(公告)号：US20210332045A1

公开(公告)日：2021-10-28

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US10131653B2

公开(公告)日：2018-11-20

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku Kamei ,  Yasuyoshi Arikawa ,  Tomohiro Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Takashi Miki ,  Jinichi Yonemori ,  Yuya Oguro ,  Takahiro Sugimoto ,  Masaki Seto ,  Goushi Nishida ,  Makoto Kamata ,  Hiroshi Imoto

IPC: C07D413/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14 ,  A61P25/20 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K31/553

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.